News + Resources
The Future of Antitrust: Key Takeaways from the 2024 National Lawyers Convention
During a recent panel discussion at the 2024 National Lawyers Convention, leading antitrust experts underscored the impact of recent policy shifts from the Federal Trade Commission (FTC) and Department of Justice (DOJ). In America’s life sciences ecosystem, the FTC...
PULSE and 35+ Other Stakeholders Urge Congress to Overturn FTC’s New HSR Rule
This week, PULSE joined over 35 leading business and industry stakeholders in calling for leaders of the House Judiciary Committee to overturn the Biden Administration’s Hart-Scott-Rodino (HSR) premerger notification rule changes.
Pro-Innovation M&A Fuels Growth, Innovation in America’s Life Sciences Industry
It’s critical that competition policies reflect the unique and fundamental role of mergers and acquisitions (M&A) in America’s life sciences industry. Policies that support pro-competitive life sciences M&A can help drive growth, incentivize investment and,...
NJBIZ Op-Ed: “Federal Anti-M&A Policy Could Undermine New Jersey’s Leadership in the Life Sciences”
In a recent op-ed for NJBIZ, Debbie Hart, President and CEO of PULSE Partner BioNJ, discusses how federal policy against mergers and acquisitions (M&A) could undermine New Jersey’s leadership in the life sciences.
Innovations Advanced by M&A: A First-in-Class Therapy for Chronic Graft-Versus-Host Disease
Mergers and acquisitions (M&A) serve as a critical bridge, enabling innovative companies of all sizes to partner and pair their promising biopharmaceutical discoveries with the resources and expertise needed to turn them into approved medicines for patients.
What They Are Saying: M&A Fuels Investment and Innovation in the American Life Sciences Industry
In the wake of the 43rd J.P. Morgan Healthcare Conference held last week, industry leaders underscored the essential role of mergers and acquisitions (M&A) in fueling America’s life sciences industry. In this annual spotlight on the life sciences industry, M&A and other collaborations were a centerfold focus as a way for companies of all sizes to navigate the long, costly journey to bring new treatments and cures to patients.
Life Sciences M&A – A Necessary and Anticipated Step in Advancing Early-Stage Breakthroughs
For many early-stage life sciences companies, mergers and acquisitions (M&A) and other collaborations are fundamental to advancing promising new discoveries. An acquisition by a larger, more established company often represents a necessary and anticipated milestone in an early-stage company’s journey to bring a new breakthrough from the lab to the patient.
New BIO & TEConomy Report and the Importance of Life Sciences M&A
A recent report from BIO and TEConomy notes that decades of growth in the life sciences have been “rooted in, and enabled by, basic and applied research and development activities; development of, and access to, a qualified and highly skilled workforce; [and]...
Innovations Advanced by M&A: A Breakthrough Precision Therapy for Rare Cancers
Life sciences companies of all sizes rely on mergers and acquisitions (M&A) to focus on what they do best, and then combine complementary resources and expertise to quickly and efficiently advance new treatments and cures to consumers. In the case of Ignyta’s acquisition by Roche, M&A played a pivotal role in accelerating a new precision therapy to patients battling rare forms of cancer.
Preserving Michigan’s Competitive Bioscience Industry
In a recent op-ed for the Detroit News, Stephen Rapundalo, President and CEO of PULSE Partner MichBio, highlights the vital role of mergers and acquisitions (M&A) in fueling innovation and competition across Michigan’s life sciences ecosystem. As Rapundalo...